Shiu-Lok Hu

Professor

Department of Pharmaceutics, Pharmaceutics Faculty

Expertise: HIV and AIDS, Infectious Diseases, Vaccines and Virology

Telephone: 206-616-9764

Fax: 206-221-6229

Email: hus@uw.edu

Website: NCBI

Education

  • Postdoctoral fellowship, Cold Spring Harbor Laboratory, New York
  • PhD in molecular biology, University of Wisconsin
  • BA with great distinction in biochemistry, University of California, Berkeley

Research Interests

  • Design and preclinical evaluation of vaccines against HIV and related primate lentiviruses
  • Structural, functional, and immunogenic studies of HIV-1 envelope proteins
  • Host-pathogen interactions in primate lentivirus infections

Biography

Dr. Hu holds a BA degree with great distinction in biochemistry from the University of California, Berkeley, and a PhD in molecular biology from the University of Wisconsin. He completed his postdoctoral training in tumor virology in Dr. J.F. Sambrook’s laboratory at Cold Spring Harbor Laboratory.

The primary interests of his laboratory are HIV pathogenesis and approaches for the prevention and treatment of AIDS. Currently, the staff pursues three major research areas: design and preclinical evaluation of vaccines against HIV and related primate lentiviruses; structural, functional, and immunogenic studies of HIV-1 envelope proteins; and host-pathogen interactions in primate lentivirus infections. His research may yield insights for novel targets for antiviral therapy and help the development of appropriate animal models to study HIV infection and AIDS.

Previously, Hu was part of a team at Oncogen that pioneered bringing the prime-boost immunization method-an early AIDS vaccine candidate-to clinical trial in 1988. This discovery laid the foundation for much of his work at the UW. His focus now is on basic research coupled with pre-clinical, proof-of-concept studies. He is currently part of three, multiyear, multi-institution National Institute of Allergy and Infectious Diseases HIV Vaccine Research and Design grants, for which his contributions total more than $9.5 million. He also has a $6.7 million Gates Foundation grant with the Consortium for AIDS Vaccine Discovery (CAVD), an international network of scientists designing novel HIV vaccine candidates and advance the most promising candidates to clinical trials.

Selected Publications

Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu S-L, Olson WC, Moore JP. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 2002; 76(6):2606-2616.

Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L, Mulvania T, Anderson D, Greenberg PD, Hu S-L, Haigwood NL. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 2003; 77:11563-11577.

Mossman SP, Pierce CC, Watson AJ, Robertson MN, Montefiori DC, Kuller L, Richardson BA, Bradshaw JC, Munn RJ, Hu S-L, Greenberg PD, Benveniste RE, Haigwood NL. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res Hum Retroviruses 2004; 20:425-434.

Zhu T, Hu S-L, Feng F, Polacino P, Liu H, Hwangbo Y, Learn GH, Mullins JI, Corey L. Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. Virology 2004; 323:208-219.

Kinman LM, Worlein JM, Leigh J, Bielefeldt-Ohmann H, Anderson DM, Hu SL, Morton WR, Anderson BD, Ho RJ. HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS. 2004 Jul 2;18(10):1363-70.

Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, Smith MZ, Agy MB, Hu SL, Krebs K, Watkins DI, O’connor DH, Davenport MP, Kent SJ. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol. 2005 May;79(9):5721-31.

Hu S-L. Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disorder 2005 5:193-201.

Rasmussen RA, Ong H, Ferrantelli F, Hu S-L, Firpo P, McKenna J, Moon J, Travis B, Ruprecht RM. DNA prime/protein boost immunization against HIV clade C: Safety and immunogenicity in mice. Vaccine 2006 24:2324-2332.

Kinman L, Bui T, Larsen K, Tsai CC, Anderson D, Morton WR, Hu SL, Ho, RJ. optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J AIDS, 2006, 42:155-161.

Jayaraman P, Zhu T, Misher L, Mohan D, Kuller L, Polacino P, Richardson BA, Bielefeldt-Ohmann H, Anderson D, Hu S-L, Haigwood NL. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol 2007, 81:822-834.

Gruber A, Chalmers A, Rasmussen RA, Ong H, Popov S, Anderson J, Hu S-L, Ruprechat RM. Dendritic cell based vaccine strategy against HIV clade C: Skewing the immune response toward TH2. Viral Immunol 2007, 20:160-9.

Polacino P, Cleveland B, Zhu Y, Kimata JT, Overbaugh J, Anderson D, Hu SL. Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. J Med Primatol. 2007 Aug;36(4-5):254-65.

Rasmussen RA, Ong H, Song R, Chenine AL, Ayash-Rashkovsky M, Hu SL, Polacino P, Else JG, Novembre FJ, Ruprecht RM; for the Clade C Program Project. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS. 2007 Sep 12;21(14):1841-8.

Brennan G, Kozyrev Y, Kodama T, Hu SL. Novel TRIM5 isoforms expressed by Macaca nemestrina. J Virol. 2007 Nov;81(22):12210-7.

Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M Jr, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol. 2007 Nov;81(22):12145-55.

Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2008 Jan;82(2):638-51.

Hu SL, Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr HIV Res. 2007 Nov;5(6):507-13. Review.

Brennan G, Kozyrev Y, Hu SL. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3569-74.